Page 221 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

200 PART 3 Therapeutic Modalities for the Cancer Patient

49. Honscha KU, Schirmer A, Reischauer A, et al.: Expression of ABC- 69. Morrison-Collister KE, Rassnick KM, Northrup NC, et al.: A
transport proteins in canine mammary cancer: consequences for combination chemotherapy protocol with mopp and ccnu consoli-
chemotherapy, Reprod Domest Anim 44(Suppl 2):218–223, 2009. dation (tufts velcap-sc) for the treatment of canine lymphoma, Vet
VetBooks.ir 50. Hifumi T, Miyoshi N, Kawaguchi H, et al.: Immunohistochemical 70. Zemann BI, Moore AS, Rand WM, et al.: A combination chemo-
Comp Oncol 1:180–190, 2003.
detection of proteins associated with multidrug resistance to anti-
cancer drugs in canine and feline primary pulmonary carcinoma,
J Vet Med Sci 72:665–668, 2010. therapy protocol (velcap-l) for dogs with lymphoma, J Vet Intern
Med 12:465–470, 1998.
51. Nowak M, Madej JA, Dziegiel P: Expression of breast cancer resis- 71. Keller ET, MacEwen EG, Rosenthal RC, et al.: Evaluation of
tance protein (bcrp-1) in canine mammary adenocarcinomas and prognostic factors and sequential combination chemotherapy with
adenomas, In Vivo 23:705–709, 2009. doxorubicin for canine lymphoma, J Vet Intern Med 7:289–295,
52. Conrad S, Viertelhaus A, Orzechowski A, et al.: Sequencing and 1993.
tissue distribution of the canine mrp2 gene compared with mrp1 72. Garrett LD, Thamm DH, Chun R, et al.: Evaluation of a 6-month
and mdr1, Toxicology 156:81–91, 2001. chemotherapy protocol with no maintenance therapy for dogs with
53. Yabuuchi H, Tanaka K, Maeda M, et al.: Cloning of the dog bile lymphoma, J Vet Intern Med 16:704–709, 2002.
salt export pump (bsep; abcb11) and functional comparison with 73. Selmic LE, Burton JH, Thamm DH, et al.: Comparison of carbo-
the human and rat proteins, Biopharm Drug Dispos 29:441–448, platin and doxorubicin-based chemotherapy protocols in 470 dogs
2008. after amputation for treatment of appendicular osteosarcoma, J Vet
54. Ramirez CJ, Minch JD, Gay JM, et al.: Molecular genetic basis Intern Med 28:554–563, 2014.
for fluoroquinolone-induced retinal degeneration in cats, Pharma- 74. Frei E, Elias A, Wheeler C, et al.: The relationship between high-
cogenet Genomics 21:66–75, 2011. dose treatment and combination chemotherapy: the concept of
55. Devita VT, Chu E: Principles of medical oncology. In Devita VT, summation dose intensity, Clin Cancer Res 4:2027, 1998.
Hellman S, Rosenberg SA, editors: Cancer: Principles & Practice 75. Simon R, Korn EL: Selecting drug combinations based on total
of Oncology, ed 8, Philadelphia, 1997, Lippincott Williams and equivalent dose (dose intensity), J Natl Cancer Inst 82:1469–1476,
Wilkins, pp 337–342. 1990.
56. Page RL, Macy DW, Ogilvie GK, et al.: Phase III evaluation of 76. Undevia SD, Gomez-Abuin G, Ratain MJ: Pharmacokinetic vari-
doxorubicin and whole-body hyperthermia in dogs with lym- ability of anticancer agents, Nat Rev Cancer 5:447–458, 2005.
phoma, Int J Hyperthermia 8:187–197, 1992. 77. Bailey DB, Rassnick KM, Erb HN, et al.: Effect of glomerular fil-
57. Carter RF, Harris CK, Withrow SJ, et al.: Chemotherapy of canine tration rate on clearance and myelotoxicity of carboplatin in cats
lymphoma with histopathological correlation- doxorubicin alone with tumors, Am J Vet Res 65:1502–1507, 2004.
compared to cop as 1st treatment regimen, J Am Anim Hosp Assoc 78. Thompson LA, Lawson AP, Sutphin SD, et al.: Description of cur-
23:587–598, 1987. rent practices of empiric chemotherapy dose adjustment in obese
58. Postorino NC, Susaneck SJ, Withrow SJ, et al.: Single agent ther- adult patients, J Oncol Pract 6:141–145, 2010.
apy with adriamycin for canine lymphosarcoma, J Am Anim Hosp 79. Hunter RJ, Navo MA, Thaker PH, et al.: Dosing chemotherapy
Assoc 25:221–225, 1989. in obese patients: actual versus assigned body surface area (BSA),
59. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al.: Doxorubicin Cancer Treat Rev 35:69–78, 2009.
alone or in combination with asparaginase, followed by cyclophos- 80. Vail DM: Supporting the veterinary cancer patient on chemo-
phamide, vincristine, and prednisone for treatment of multicentric therapy: neutropenia and gastrointestinal toxicity, Top Companion
lymphoma in dogs: 121 cases (1987–1995), J Am Vet Med Assoc Anim Med 24:122–129, 2009.
210:512–516, 1997. 81. Valanis B, Vollmer WM, Steele P: Occupational exposure to anti-
60. Mutsaers AJ, Glickman NW, DeNicola DB, et al.: Evaluation of neoplastic agents: self-reported miscarriages and stillbirths among
treatment with doxorubicin and piroxicam or doxorubicin alone nurses and pharmacists, J Occup Environ Med 41:632–638, 1999.
for multicentric lymphoma in dogs, J Am Vet Med Assoc 220:1813– 82. Sessink PJ, Kroese ED, van Kranen HJ, et al.: Cancer risk assess-
1817, 2002. ment for health care workers occupationally exposed to cyclophos-
61. Cotter SM: Treatment of lymphoma and leukemia with cyclophos- phamide, Int Arch Occup Environ Health 67:317–323, 1995.
phamide, vincristine, and prednisone.1. Treatment of dogs, J Am 83. Ebert U, Loffler H, Kirch W: Cytotoxic therapy and pregnancy,
Anim Hosp Assoc 19:159–165, 1983. Pharmacol Ther 74:207–220, 1997.
62. MacEwen EG, Brown NO, Patnaik AK, et al.: Cyclic combina- 84. Autio K, Rassnick KM, Bedford-Guaus SJ: Chemotherapy dur-
tion chemotherapy of canine lymphosarcoma, J Am Vet Med Assoc ing pregnancy: a review of the literature, Vet Comp Oncol 5:61–75,
178:1178–1181, 1981. 2007.
63. MacEwen EG, Hayes AA, Matus RE, et al.: Evaluation of some 85. Kicenuik K, Northrup N, Dawson A, et al.: Treatment time, ease
®
prognostic factors for advanced multicentric lymphosarcoma in the of use and cost associated with use of equashield, Phaseal , or no
dog: 147 cases (1978–1981), J Am Vet Med Assoc 190:564–568, closed system transfer device for administration of cancer chemo-
1987. therapy to a dog model, Vet Comp Oncol 15:163–173, 2017.
64. Khanna C, Lund EM, Redic KA, et al.: Randomized controlled 86. Pharmacists ASoH- S: Ashp guidelines on handling hazardous
trial of doxorubicin versus dactinomycin in a multiagent protocol drugs, Am J Health Syst Pharm 63:1172, 2006.
for treatment of dogs with malignant lymphoma, J Am Vet Med 87. Knobloch A, Mohring SA, Eberle N, et al.: Cytotoxic drug residues
Assoc 213:985, 1998. in urine of dogs receiving anticancer chemotherapy, J Vet Intern
65. Greenlee PG, Filippa DA, Quimby FW, et al.: Lymphomas in Med 24:384–390, 2010.
dogs: a morphologic, immunologic, and clinical study, Cancer 88. Evans WE, Relling MV: Clinical pharmacokinetics- pharmacodynamics
66:480–490, 1990. of anticancer drugs, Clin Pharmacokinet 16:327–336, 1989.
66. Stone MS, Goldstein MA, Cotter SM: Comparison of 2 protocols 89. Eckhoff GA: Mechanisms of adverse drug-reactions and interac-
for induction of remission in dogs with lymphoma, J Am Anim tions in veterinary-medicine, J Am Vet Med Assoc 176:1131–1133,
Hosp Assoc 27:315–321, 1991. 1980.
67. Myers NC, Moore AS, Rand WM, et al.: Evaluation of a multidrug 90. He SM, Yang AK, Li XT, et al.: Effects of herbal products on the
chemotherapy protocol (acopa II) in dogs with lymphoma, J Vet metabolism and transport of anticancer agents, Expert Opin Drug
Intern Med 11:333–339, 1997. Metab Toxicol 6:1195–1213, 2010.
68. Boyce KL, Kitchell BE: Treatment of canine lymphoma with
COPLA/LVP, J Am Anim Hosp Assoc 36:395–403, 2000.